Atossa Therapeutics (ATOS) said Wednesday that the US Patent and Trademark Office granted a new patent covering highly pure and stable enteric oral formulations of (Z)-endoxifen, a breast cancer treatment

The patent includes 58 claims, encompassing various formulations and therapeutic methods for hormone-dependent breast and reproductive tract disorders, the company said.

Atossa shares rose 1.9% in recent Wednesday trading.

Price: 0.81, Change: +0.02, Percent Change: +1.89